SCHEMBL31358872

SCHEMBL31358872

O=C1C(=Cc2ccc(-c3ccc(Br)c(Cl)c3)o2)C(=O)c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.60
MEN1 O00255 6/20 0.60
AKT1 P31749 1/20 0.58
POLB P06746 8/20 0.55
MAPT P10636 7/20 0.55
L3MBTL1 Q9Y468 6/20 0.55
TDP1 Q9NUW8 4/20 0.55
PKM P14618 3/20 0.55
HPGD P15428 2/20 0.55
RECQL P46063 1/20 0.55
MCL1 Q07820 1/20 0.55
KDM4E B2RXH2 4/20 0.51
SIRT2 Q8IXJ6 1/20 0.49
CTDSP1 Q9GZU7 3/20 0.48
MAPK1 P28482 1/20 0.48
ALDH1A1 P00352 5/20 0.46
PTPN5 P54829 2/20 0.46
PPM1G O15355 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN7 P35236 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358776 0.88 SIRT2 (0.62) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358693 0.82 AKT1 (0.58) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358844 0.82 MEN1 (0.60) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358841 0.82 AKT1 (0.73) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358688 0.82 HTRA2 (0.66) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358866 0.81 KMT2A (0.69) KMT2AMEN1AKT1POLBMAPT
SCHEMBL13479578 0.81 MEN1 (0.69) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358681 0.81 MEN1 (0.69) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358753 0.81 POLB (0.58) KMT2AMEN1AKT1POLBMAPT
SCHEMBL31358709 0.81 MEN1 (0.64) KMT2AMEN1AKT1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 KMT2A 1043/4885MEN1 2467/4885AKT1 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.